ClinicaliQ Trial Snapshot
- A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) — Recruiting • Phase II • NCT07533006.
- Trial testing new drug LY4005130 versus placebo for severe hair loss, measuring effectiveness, safety, and how body processes drug.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last approximately 48 weeks, including screening. Conditions: Alopecia Areata Interventions: LY4005130, Placebo Lead Sponsor: Eli Lilly…